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Charles W Gay1* and Mark D Bishop2,3Abstract
Over the decades, research into placebo responses has shed light onto several endogenous (i.e. produced from
within) mechanisms underlying modulation of pain perception initiated after the administration of inert substances
(i.e. placebos). Chiropractors and manual therapists should embrace analgesic-placebo-research in an attempt
to maximize clinical benefit. Historical views that placebo responses are fake, passive, undesirable, and require
deception and therefore should be minimized and avoided in clinical practice are outdated. Further, statements that
contend the placebo response represents a single mechanism are overly simplistic. This commentary will discuss
research that shows that there are several active biological processes underlying modulation of pain perception
involved in placebo analgesia and its counterpart nocebo hyperalgesia. We contend that it is highly likely that, to
some extent, all of these biological processes are engaged, in varying degrees, following all interventions and
represent endogenous pain modulating processes. Failure, of chiropractors and manual therapists, to embrace a
more contemporary view of analgesic-placebo-research serves as a barrier to transferring knowledge into clinical
practice and represents a missed opportunity to improve the delivery of current treatments.
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Evidence-based medicine deals with the use of current
best evidence in clinical decision-making and other as-
pects of patient care. The assumption that simply having
the evidence available or providing authoritative clinical
practice guidelines will result in practice change and im-
proved patient outcomes is incorrect [1,2]. A number of
physician behaviors have been identified that act as bar-
riers to translating evidence into clinical practice [3].
Two domains of those barriers are physician’s knowledge
and attitudes. This commentary addresses knowledge
awareness and outdated attitudes surrounding the clinical
improvement seen following the administration of a pla-
cebo. By addressing these potential barriers chiropractors
and manual therapists may be more open to analgesic-
placebo-research and its counterpart hyperalgesia-nocebo-
research. In turn, clinical practice may be influenced by
knowledge gained from this field, applying evidence to* Correspondence: chaz.gay@ufl.edu
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reproduction in any medium, provided the ordecision-making and the context in which interventions
are delivered with a goal of improving patient outcomes.Main text
Misconceptions about placebo responses continue in the
general public and among healthcare professionals [4,5].
There has been a push for healthcare professionals to
re-think what a placebo response represents and the ap-
plicability of knowledge gained from placebo-analgesia-
research that can be applied ethically in clinical practice
[6-12]. Rethinking placebo and nocebo responses as en-
dogenous modulatory mechanisms broadens the focus of
care beyond just the intervention to include the context
in which interventions are delivered. Historical views
that placebo responses represent fake, passive, and un-
desirable results; require deception; and should be mini-
mized and avoided in clinical practice continue today
among healthcare providers. Further, the placebo response
has been described as a single mechanism through which
an intervention may induce a positive therapeutic outcome
[9]. Harboring such views may bias manual therapy practi-
tioners away from valuable clinical evidence that maytral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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presents research that opposes these views.
Changes in the perceived intensity of pain are often at-
tributed to a variety of factors lumped into three board
categories: (1) condition related factors, (2) the specific
effects of treatment, and/or (3) treatment contextual ef-
fects [13]. Condition related factors include the natural
course of the condition and regression to the mean. Spe-
cific treatment effects are the unique effects associated
with the ‘active’ ingredient of the treatment. Treatment
context includes a host of signs, symbols and physician
interactions that convey information to the individual.
In recent years, researchers have used placebo-analgesia
and its negative equivalent, nocebo-hyperalgesia to inves-
tigate the neuronal underpinnings of treatment contextual
effects. Although, these three categories are practical and
useful, they can create a misconception that there are
unique biological pathways that do not overlap or inter-
act underlying the categories. This misconception is
highlighted by the notion that a predictable estimate of
change in pain perception can be determined simply by a
treatment’s active biological properties.
For example, findings from one study significantly chal-
lenge the convention that an active biological agent pro-
duces a consistent therapeutic effect within an individual.
By convention, researchers acknowledge that the active
biological agent in a drug will vary across people, depend-
ing on a multitude of personal factors. However, what is
not acknowledged so frequently is that within one individ-
ual, the therapeutic effect can significantly vary. By experi-
mentally manipulating an individual’s expectation through
instructional sets, it was shown that the therapeutic effect
of the active ingredient of remifentanil, a potent synthetic
μ-opioid agonist, can be significantly modulated [14]. The
study manipulated subjects’ expectations by instructing
them that remifentanil is a widely used opioid that relieves
pain when infused intravenously, but can worsen pain
when the infusion ceases [14]. Hidden administration of
the drug produced less perceived pain than baseline, open
administration of the drug produced significantly more
hypoalgesia than hidden administration and when the
drug was continuously administered but the subjects were
told it had stopped, the perception of pain retuned to
baseline values [14]. The estimated therapeutic effect size
of the active ingredient in remifentanil spanned from no
effect to a moderate effect, depending on the expectancy
created by the instructional set.
Embedded in every pain-relieving treatment are con-
textual effects. Physician interactions, signs and symbols
convey information to the individual with the potential
for producing therapeutic and counter-therapeutic re-
sponses (ie placebo and nocebo responses respectively)
[15]. The estimated therapeutic effect of treatment con-
text following the administration of an inert substancehas been shown to be substantial, albeit variable [15-21].
One factor that is not causing the therapeutic effect is
the inert substance (ie placebo). Therefore, placebo-
analgesia-research provides valuable information about
the context in which interventions are delivered. Research
into principle mediators of the contextual effects suggest
expectancy, desire for a positive outcome and classical
conditioning account for a significant portion of the vari-
ance in contextual effects [22-24]. Chiropractors and man-
ual therapists should be aware that the context in which
they deliver their interventions is as important as the
intervention they are giving. Further evidence suggest-
ing the effectiveness of a manual therapy intervention is
influenced by patient’s expectation comes from a study
published by Bialosky et al. [25]. The study showed that
by using different instructional sets to positively, nega-
tively and neutrally influence the subjects expectation,
the effect of spinal manipulation on a dynamic pain sen-
sitivity measure (temporal summation of second pain)
varied [25].
Placebo-analgesia-research has also shown that decep-
tion is not integral to inducing a placebo response. One
study administered open labeled placebos with patient
education that described an active biological pathway for
symptom improvement [26]. In this study, the investiga-
tors told irritable bowel syndrome (IBS) subjects, that
they would be randomized to receive either a placebo
sugar pill or no treatment. Subjects receiving the placebo
pill were told placebos have been found to produce cli-
nically effective results though a mind-body connection
and that by taking the pill, the subjects would be harnes-
sing their own recuperative powers. Greater clinical im-
provement was found in the placebo group compared to
the no-treatment group [26]. Another study examined
the repeatability of contextual effects after subjects were
told they received an inert substance. In this study, indi-
viduals, who received inert pain-relieving cream and ex-
perienced pain reductions, were then told they had
received a placebo cream. On a subsequent visit those
same individuals were again able to experience pain re-
lief a second time using an inert cream [27]. Both of
these studies challenge deception’s role as a necessary
component of the context in which an inert treatment is
delivered that produces a positive therapeutic effect.
Finally, placebo-analgesia-research has shed light onto
neural mechanisms underlying endogenous pain modu-
lation. Cortical networks involved in processing and
modulating the pain experience have been identified and
continue to be reinvestigated, redefined and undergo re-
conceptualization. Activity in these cortical networks in-
fluence the perception of pain and modulation can be
inhibitory or facilitatory. Research has identified various
neurotransmitters including opioids, cannabinoids, do-
pamines and cholecystokinins, that are used within these
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lowing the administration of an inert substance to a sin-
gle mechanism, or terming it a placebo mechanism fails
to account for the numerous neural and other biological
pathways involved in producing and influencing the per-
ception of pain [32,33].
Conclusion
Over the decades, research into placebo responses has
shed light onto several endogenous (i.e. produced from
within) mechanisms underlying modulation of pain per-
ception initiated by the administration of inert substances
(i.e. placebos/nocebos). In addition, this growing body of
work emphasizes the need for chiropractors’ and manual
therapists’ to be more alert to, and embrace, ‘psychologic-
ally informed practice’; that is, practice in which recogni-
tion of neural mechanisms is equally as important as
identification of structural pathology. Chiropractors and
manual therapists should embrace analgesic-placebo-
research in an attempt to maximize endogenous pain re-
lieving mechanisms to produce maximum clinical benefit.
Historical views that placebo responses are fake, passive,
undesirable, and require deception and therefore should
be minimized and avoided in clinical practice are out-
dated. Further, statements that contend the placebo re-
sponse represents a single mechanism are too simplistic.
Instead, in this commentary the authors discussed how
several active biological processes underlie analgesic-
placebo responses. We contend that it is highly likely that
to some extent all of these biological processes, which rep-
resent endogenous pain relieving processes, are engaged
to various degrees following all interventions that produce
a positive clinical outcome.
Failure to embrace a more contemporary view of
analgesic-placebo-research may negatively bias chiro-
practors’ and manual therapists’ opinions about the po-
tential clinical value of results emerging from this field.
These biases serve as a barrier to successfully translat-
ing potential benefits for patients into clinical practice
in an ethical manner. Analgesic-placebo-research pro-
vides insight on how to improve the delivery of current
treatments by optimizing clinical benefit and matching
the right treatment to the right spinal pain patient at
the right time.
Competing interests
The authors of this manuscript attest there are no conflicts of interest to report.
Authors’ contributions
CWG and MDB contributed equally to the concept, the drafting, and critical
revision of the manuscript. All authors read and approved the final
manuscript.
Acknowledgements
This manuscript was written while CWG received support from the University
of Florida Alumni Fellowship, NCMIC Foundation and the National Center of
Complementary and Alternative Medicine (F32 AT007729-01A1), MDBreceived support from the National Center of Complementary and Alterna-
tive Medicine (R01AT006334).
Author details
1Rehabilitation Science Doctoral Student, University of Florida, Gainesville,
Florida, USA. 2Associate Professor, Department of Physical Therapy, University
of Florida, Gainesville, Florida, USA. 3Center for Pain Research & Behavioral
Health, University of Florida, Gainesville, Florida, USA.
Received: 29 August 2013 Accepted: 7 January 2014
Published: 3 February 2014
References
1. Mafi JN, McCarthy EP, Davis RB, Landon BE: Worsening trends in the
management and treatment of back pain. JAMA Intern Med 2013,
173(17):1573–81.
2. National Research Council: Relieving Pain in America: Blueprint for
Transofrming Prevention, Care, Education, and Research. Washington, DC:
The National Academies Press; 2011.
3. Pierson DJ: Translating evidence into practice. Respiratory care 2009,
54:1386–1401.
4. Bishop FL, Jacobson EE, Shaw JR, Kaptchuk TJ: Scientific tools, fake
treatments, or triggers for psychological healing: How clinical trial
participants conceptualise placebos. Soc Sci Med 2012, 74(5):767–74.
5. Kisaalita NR, Robinson ME: Analgesic placebo treatment perceptions:
acceptability, efficacy, and knowledge. J Pain 2012, 13:891–900.
6. Miller FG, Kaptchuk TJ: The power of context: reconceptualizing the
placebo effect. J R Soc Med 2008, 101:222–225.
7. Brody H, Colloca L, Miller FG: The placebo phenomenon: implications for
the ethics of shared decision-making. J Gen Intern Med 2012, 27:739–742.
8. Kisaalita NR, Roditi D, Robinson ME: Factors affecting placebo
acceptability: deception, outcome, and disease severity. J Pain 2011,
12:920–928.
9. Bialosky JE, Bishop MD, George SZ, Robinson ME: Placebo response to
manual therapy: something out of nothing? J Man Manip Ther 2011,
19:11–19.
10. Linde K, Fassler M, Meissner K: Placebo interventions, placebo effects and
clinical practice. Philos Trans R Soc Lond B Biol Sci 2011, 366:1905–1912.
11. Benz LN, Flynn TW: Placebo, nocebo, and expectations: leveraging
positive outcomes. J Orthop Sports Phys Ther 2013, 43:439–441.
12. Benedetti F, Amanzio M: Mechanisms of the placebo response.
Pulm Pharmacol Ther 2013.
13. Fillingim RB, Price DD: What is controlled for in placebo-controlled trials?
Mayo Clin Proc 2005, 80:1119–1121.
14. Bingel U, Wanigasekera V, Wiech K, Ni Mhuircheartaigh R, Lee MC, Ploner M,
Tracey I: The effect of treatment expectation on drug efficacy: imaging
the analgesic benefit of the opioid remifentanil. Sci Transl Med 2011,
3:70ra14.
15. Miller FG, Colloca L: Semiotics and the placebo effect. Perspect Biol Med
2010, 53:509–516.
16. Price DD, Finniss DG, Benedetti F: A comprehensive review of the placebo
effect: recent advances and current thought. Annu Rev Psychol 2008,
59:565–590.
17. Hrobjartsson A: The uncontrollable placebo effect. Eur J Clin Pharmacol
1996, 50:345–348.
18. Hrobjartsson A, Gotzsche PC: Is the placebo powerless? An analysis of
clinical trials comparing placebo with no treatment. N Engl J Med 2001,
344:1594–1602.
19. Hrobjartsson A, Gotzsche PC: Is the placebo powerless? Update of a
systematic review with 52 new randomized trials comparing placebo
with no treatment. J Intern Med 2004, 256:91–100.
20. Hrobjartsson A, Gotzsche PC: Unsubstantiated claims of large effects of
placebo on pain: serious errors in meta-analysis of placebo analgesia
mechanism studies. J Clin Epidemiol 2006, 59:336–338. discussion 339–341.
21. Benedetti F, Carlino E, Pollo A: How Placebos Change the Patient’s Brain.
Neuropsychopharmacology 2011, 36:339–354.
22. Vase L, Petersen GL, Riley JL 3rd, Price DD: Factors contributing to large
analgesic effects in placebo mechanism studies conducted between
2002 and 2007. Pain 2009, 145:36–44.
23. Finniss DG, Kaptchuk TJ, Miller F, Benedetti F: Biological, clinical, and
ethical advances of placebo effects. Lancet 2010, 375:686–695.
Gay and Bishop Chiropractic & Manual Therapies 2014, 22:6 Page 4 of 4
http://www.chiromt.com/content/22/1/624. George SZ, Robinson ME: Dynamic nature of the placebo response.
J Orthop Sports Phys Ther 2010, 40:452–454.
25. Bialosky JE, Bishop MD, Robinson ME, Barabas JA, George SZ: The influence
of expectation on spinal manipulation induced hypoalgesia: an
experimental study in normal subjects. BMC Musculoskelet Disord 2008,
9:19.
26. Kaptchuk TJ, Friedlander E, Kelley JM, Sanchez MN, Kokkotou E, Singer JP,
Kowalczykowski M, Miller FG, Kirsch I, Lembo AJ: Placebos without
deception: a randomized controlled trial in irritable bowel syndrome.
PLoS One 2011, 5:e15591.
27. Chung SK, Price DD, Verne GN, Robinson ME: Revelation of a personal
placebo response: its effects on mood, attitudes and future placebo
responding. Pain 2007, 132:281–288.
28. Colloca L, Benedetti F: Nocebo hyperalgesia: how anxiety is turned into
pain. Curr Opin Anaesthesiol 2007, 20:435–439.
29. Benedetti F: Placebo-induced improvements: how therapeutic rituals
affect the patient’s brain. J Acupunct Meridian Stud 2012, 5:97–103.
30. Benedetti F, Thoen W, Blanchard C, Vighetti S, Arduino C: Pain as a reward:
changing the meaning of pain from negative to positive co-activates
opioid and cannabinoid systems. Pain 2013, 154:361–367.
31. Zubieta JK, Stohler CS: Neurobiological mechanisms of placebo
responses. Ann N Y Acad Sci 2009, 1156:198–210.
32. Tracey I: Getting the pain you expect: mechanisms of placebo, nocebo
and reappraisal effects in humans. Nat Med 2010, 16:1277–1283.
33. Benedetti F: What do you expect from this treatment? Changing our
mind about clinical trials. Pain 2007, 128:193–194.
doi:10.1186/2045-709X-22-6
Cite this article as: Gay and Bishop: Research on placebo analgesia is
relevant to clinical practice. Chiropractic & Manual Therapies 2014 22:6.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
